CAS 69655-05-6|2',3'-Dideoxyinosine

Introduction：Basic information about CAS 69655-05-6|2',3'-Dideoxyinosine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. 2',3'-Dideoxyinosine BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
MUTATION DATA
5. Safety Information
6. Customs
7. Articles85
8. Synonyms

Common Name	2',3'-Dideoxyinosine
CAS Number	69655-05-6	Molecular Weight	236.227
Density	1.8±0.1 g/cm3	Boiling Point	531.2±60.0 °C at 760 mmHg
Molecular Formula	C₁₀H₁₂N₄O₃	Melting Point	193-195 °C
MSDS	ChineseUSA	Flash Point	275.0±32.9 °C

Names

Name	didanosine
Synonym	More Synonyms

2',3'-Dideoxyinosine BiologicalActivity

Description	Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.Target: NRTIs; HIVDidanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy [2].
Related Catalog	Signaling Pathways >>Anti-infection >>HIVSignaling Pathways >>Anti-infection >>Reverse TranscriptaseResearch Areas >>Infection
References	[1]. Knupp, C.A., et al., Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther, 1991. 49(5): p. 523-35. [2]. Bissuel, F., et al., Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med, 1994. 235(4): p. 367-71.

Description

Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.Target: NRTIs; HIVDidanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy [2].

Related Catalog

Signaling Pathways >>Anti-infection >>HIVSignaling Pathways >>Anti-infection >>Reverse TranscriptaseResearch Areas >>Infection

References

[1]. Knupp, C.A., et al., Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther, 1991. 49(5): p. 523-35.

[2]. Bissuel, F., et al., Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med, 1994. 235(4): p. 367-71.

Chemical & Physical Properties

Density	1.8±0.1 g/cm3
Boiling Point	531.2±60.0 °C at 760 mmHg
Melting Point	193-195 °C
Molecular Formula	C₁₀H₁₂N₄O₃
Molecular Weight	236.227
Flash Point	275.0±32.9 °C
Exact Mass	236.090942
PSA	93.03000
LogP	-1.31
Vapour Pressure	0.0±1.5 mmHg at 25°C
Index of Refraction	1.798
InChIKey	BXZVVICBKDXVGW-NKWVEPMBSA-N
SMILES	O=c1[nH]cnc2c1ncn2C1CCC(CO)O1
Storage condition	2-8°C
Stability	Stable. Combustible. Incompatible with strong oxidizing agents.
Water Solubility	1-5 g/100 mL at 21 ºC

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: NM7460700

CHEMICAL NAME :: Inosine, 2',3'-dideoxy-

CAS REGISTRY NUMBER :: 69655-05-6

LAST UPDATED :: 199803

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C10-H12-N4-O3

MOLECULAR WEIGHT :: 236.26

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 2340 mg/kg/34W-I

TOXIC EFFECTS :: Liver - fatty liver degeneration Liver - jaundice, cholestatic Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 28 gm/kg/28D-I

TOXIC EFFECTS :: Immunological Including Allergic - decrease in humoral immune response

MUTATION DATA

TEST SYSTEM :: Rodent - mouse

DOSE/DURATION :: 6 gm/kg/3D (Intermittent)

REFERENCE :: EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 18,168,1991

Safety Information

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes	C
Risk Phrases	R34
Safety Phrases	S26-S27-S36/37/39-S45
RIDADR	NONH for all modes of transport
WGK Germany	2
RTECS	NM7460700
HS Code	2942000000

Customs

HS Code	2942000000

Articles85

Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.

Antimicrob. Agents Chemother. 51 , 2531-9, (2007)

Nucleoside analogs are associated with various mitochondrial toxicities, and it is becoming increasingly difficult to accommodate these differences solely in the context of DNA polymerase gamma inhibi...

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chem. Res. Toxicol. 23 , 171-83, (2010)

Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental...

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

J. Sci. Ind. Res. 65(10) , 808, (2006)

Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ...

Synonyms

9-[(2R,5S)-5-(hydroxyméthyl)tétrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one

DDI

Videx

9-[(2R,5S)-5-(Hydroxymethyl)tetrahydro-2-furanyl]-1,9-dihydro-6H-purin-6-one

9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-9H-purin-6-ol

MFCD00077728

Inosine, 2’,3’-dideoxy-

VIDEX EC

2',3'-Dideoxyinosine

9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one

6H-Purin-6-one, 1,9-dihydro-9-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-

INOSINE, 2',3'-DIDEOXY-

Dideoxyinosine

Didanosine

9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-on

didanosinum [INN_la]

Recommended......